Gyre Therapeutics (GYRE) Cash from Investing Activities (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Cash from Investing Activities of -$3.1 million for Q1 2026, down 255.31% year-over-year from $2.0 million in Q1 2025, and down 265.31% quarter-over-quarter from $1.8 million in Q4 2025.
Gyre Therapeutics (GYRE) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Cash from Investing Activities for 17 consecutive years, with -$3.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 255.31% year-over-year to -$3.1 million; the TTM figure through Mar 2026 stood at -$5.5 million (up 48.62% YoY), while the FY2025 annual figure was -$474000.0, up 97.62% from the prior year.
- Cash from Investing Activities fell to -$3.1 million in Q1 2026 per GYRE's latest filing, from $1.8 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $52.9 million in Q2 2022 and bottomed at -$69.2 million in Q4 2022.
- Historically, Cash from Investing Activities has averaged -$3.6 million across 5 years, with a median of -$2.7 million in 2024.
- On a YoY basis, Cash from Investing Activities climbed as much as 393.94% in 2022 and fell as far as 2514.13% in 2022.
- Gyre Therapeutics' Cash from Investing Activities stood at -$69.2 million in 2022, then surged by 101.94% to $1.3 million in 2023, then sank by 249.66% to -$2.0 million in 2024, then jumped by 192.22% to $1.8 million in 2025, then sank by 265.31% to -$3.1 million in 2026.
- Business Quant data shows GYRE's Cash from Investing Activities at -$3.1 million in Q1 2026, $1.8 million in Q4 2025, and -$1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 9.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.76 Mn |
| Jun 30, 2026 | 9.76 Mn |
| Mar 31, 2026 | -3.06 Mn |
| Mar 31, 2026 | -3.06 Mn |
| Dec 31, 2025 | 1.85 Mn |
| Dec 31, 2025 | 1.85 Mn |
| Sep 30, 2025 | -1.25 Mn |
| Sep 30, 2025 | -1.25 Mn |
| Jun 30, 2025 | -3.04 Mn |
| Jun 30, 2025 | -3.04 Mn |
| Mar 31, 2025 | 1.97 Mn |
| Mar 31, 2025 | 1.97 Mn |
| Dec 31, 2024 | -2.00 Mn |
| Dec 31, 2024 | -2.00 Mn |
| Sep 30, 2024 | -2.39 Mn |
| Sep 30, 2024 | -2.39 Mn |
| Jun 30, 2024 | -8.27 Mn |
| Jun 30, 2024 | -8.27 Mn |
| Mar 31, 2024 | -7.22 Mn |
| Mar 31, 2024 | -7.22 Mn |